- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04497233
Prediction Model of Peripheral Pulmonary Lesions Based on R-EBUS Image (R-EBUS)
July 29, 2020 updated by: Jiayuan Sun, Shanghai Chest Hospital
Prediction Model of Benign and Malignant Peripheral Pulmonary Lesions Based on Image of Radial Endobronchial Ultrasound
Peripheral pulmonary lesions(PPLs) have a wide spectrum of diseases, and the diagnosis will affect the treatment strategy and prognosis.
Radial endobronchial ultrasound (R-EBUS) can be used for non-invasive diagnosis of PPLs, and the supplement pathological diagnosis results of EBUS-TBLB, which has important clinical application value.
This project intends to select representative images from R-EBUS dynamic videos for qualitative and quantitative analysis, to establish and verify the diagnostic evaluation system of R-EBUS forPPLs.
Then build 1,000 R-EBUS image databases of PPLs, train deep learning networks for automatic extraction and diagnosis of target areas, and automatically extract representative images from videos to establish a benign and malignant prediction model of PPLs.
We will provide reliable theoretical basis for the diagnosis of PPLs, and optimize the diagnosis and treatment method.The network would be prospectively verified through 300 R-EBUS images from multi centers.
Study Overview
Status
Unknown
Conditions
Detailed Description
PPLs are lesions at tertiary bronchus and above.
The lesion cannot be seen by conventional bronchoscopy and the diagnosis will affect the treatment strategy and prognosis.
R-EBUS can be used for non-invasive diagnosis of PPLs, and the supplement pathological diagnosis results of EBUS-TBLB.
During the procedure, target PPLs are examined by ultrasound host (EU-ME2, Olympus, Tokyo, Japan) equipped with Doppler function and ultrasound probe .
The bronchoscope reaches the distal as far as possible according to the predetermined position on chest CT or positron emission tomography-computed tomography (PET-CT) .
The R-EBUS probe is inserted into the working channel of the bronchoscope, and gradually approaches the target PPL to obtain R-EBUS image.
According to the characteristics such as within or adjacent to image, the probe scan the lesion from the near end to the far end and record the video.
The recording time is required longer than 10 seconds.
After selecting a typical R-EBUS image, freeze the image and take a screenshot.
The long and short diameter of the lesion will be measured.
This project includes three parts: preliminary construction and evaluation of R-EBUS image system for benign and malignant PPLs, construction of R-EBUS artificial intelligence prediction model and multi-center prospective validation of the prediction model.
A total of 1000 patients will be enrolled to construct diagnostic model and 300 are enrolled to verify the diagnostic effiency.
Study Type
Observational
Enrollment (Anticipated)
1300
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Shanghai, China
- Recruiting
- Shanghai Chest Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
The population of this study are those who meet the inclusion and exclusion criteria.
Description
Inclusion Criteria:
- Patients with PPLs in Chest CT or PET / CT;
- Chest CT or PET / CT shows PPLs with diameter greater than 8 mm;
- Patients agree to perform EBUS-TBLB and sign the informed consent.
Exclusion Criteria:
- Thin-layer Chest CT or PET / CT indicates lack of bronchial access to PPLs;
- Patients refuse to participate in this clinical trial;
- Patients with severe cardiopulmonary dysfunction or other indications that not allowed for bronchoscopy;
- Visible lesions in the lumen during conventional bronchoscopy;
- Patients have other related contraindications of bronchoscopy;
- Patients have other reasons unfit for this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Prospectively validation group
Two diagnosis methods will be used in the prospective validation section, one is traditional qualitative and quantitative method, the other is artificial intelligence prediction model based on videos to compare the diagnostic efficacy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diagnostic efficacy of R-EBUS prediction model.
Time Frame: 18 months
|
Diagnostic efficacy includes sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diagnostic efficacy of traditional qualitative and quantitative methods
Time Frame: 18 months
|
Diagnostic efficacy includes sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy
|
18 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
July 1, 2018
Primary Completion (ANTICIPATED)
September 30, 2020
Study Completion (ANTICIPATED)
March 31, 2021
Study Registration Dates
First Submitted
July 19, 2020
First Submitted That Met QC Criteria
July 29, 2020
First Posted (ACTUAL)
August 4, 2020
Study Record Updates
Last Update Posted (ACTUAL)
August 4, 2020
Last Update Submitted That Met QC Criteria
July 29, 2020
Last Verified
July 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHCHE202001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diagnoses Disease
-
Inspirata Europe Ltd.CompletedDiagnoses DiseaseUnited Kingdom
-
Nazan Kocak TopbasMersin UniversityNot yet recruiting
-
Brigham and Women's HospitalCricoActive, not recruiting
-
Istanbul Bilgi UniversityUnknown
-
Hospital do CoracaoCompletedInpatient Facililty DiagnosesBrazil
-
Nagaoka Red Cross HospitalUnknownOther Diagnoses and ConditionsJapan
-
Institute of Liver and Biliary Sciences, IndiaCompleted
-
Doha FahmyAssiut UniversityUnknownDiagnoses Disease
-
Aalborg University HospitalAarhus University Hospital; Rigshospitalet, Denmark; Horsens Hospital; Kolding... and other collaboratorsCompletedPreimplantation Genetic Diagnosis | Prenatal DiagnosesDenmark